Merck's KEYTRUDA Regimen Receives FDA Priority Review for Muscle-Invasive Bladder Cancer

Merck & Co., Inc. announced that its KEYTRUDA regimen for the treatment of muscle-invasive bladder cancer (MIBC) has been granted priority review by the U.S. Food and Drug Administration (FDA). This designation allows for a faster evaluation of the potential treatment, marking a significant step toward offering a new option for patients. The FDA's priority review is assigned to drugs that address a serious medical need and demonstrate significant improvement potential over existing therapies. The KEYTRUDA regimen is designed for use before and after surgery in MIBC patients, aiming to reduce the risk of disease recurrence. Merck stated that results from clinical trials evaluating the efficacy and safety of this regimen will be considered during the FDA review. The company continues its efforts to improve survival and quality of life for patients with aggressive cancers like MIBC. KEYTRUDA stands out as one of Merck's key immunotherapy products. The FDA's priority review decision could accelerate the approval process for this new indication and contribute to the company's oncology portfolio. This is not investment advice.